Nicholas Johnson, MD
Neurology · Salt Lake City, UTNPI 1497969943
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $64,173 of the $80,117 with a category attached, or 80.1%. 12 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 56.6% of the total. Among neurology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $1271.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$45K
- Sanofi-aventis U.S. LLC$6K
- Vertex$6K
- Argenx US, Inc.$4K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Sanofi$3K
- plus $11K from 6 others
Across 83 payments — averaging $43,729 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1.3M
- Novartis$977K
- Vertex$942K
- Genentech, Inc.$259K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$123K
- CSL Behring$32K
- plus $21K from 2 others
What the payments were for
- Consulting fees$64,17380%
- Speaking & faculty fees$2,3683%
- Travel & lodging$4,4216%
- Food & beverage$3,6445%
- Education$5,5117%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 34 | $45,332 |
| Sanofi-aventis U.S. LLC | 3 | $6,496 |
| Vertex | 5 | $5,901 |
| Argenx US, Inc. | 3 | $4,250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $3,539 |
| Sanofi | 1 | $3,355 |
| Novartis | 5 | $3,300 |
| Lupin Inc. | 1 | $2,368 |
| Regeneron | 2 | $2,295 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,187 |
| Merck | 1 | $1,030 |
| Biogen | 2 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Exondys 51$13,615
- VYVGART HYTRULO$2,000
- VYVGART$1,750
How this compares
$80,117 in reported general payments places this provider in the 90th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyclarysOmaveloxolone | 34 | $1,089,013 |
| EvrysdiRisdiplam | 20 | $657,628 |
| Pregabalin | 26 | $2,455 |
| Mexiletine Hcl | 14 | $1,207 |
| Gabapentin | 24 | $449 |
| Modafinil | 12 | $405 |
| Nortriptyline Hcl | 13 | $179 |
| Baclofen | 13 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenSkyclarys | $65 | $1,089,01334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 157 neurology providers in Utah.
Other neurology in Salt Lake City
- Timothy WestSalt Lake City$856K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Lucy DewittSalt Lake City$81K
- Viktoria KaplanSalt Lake City$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.